{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:26:08Z","timestamp":1787199968067,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Urol."],"abstract":"<jats:p>\n                    Hereditary leiomyomatosis and renal cell carcinoma (HLRCC), caused by germline\n                    <jats:italic>FH<\/jats:italic>\n                    mutations, is a rare autosomal dominant syndrome. This report details a 42-year-old woman with aggressive FH-deficient renal cell carcinoma (RCC) and multiple uterine leiomyomas. Radical nephrectomy and subsequent hysterectomy confirmed FH-deficient tumors via immunohistochemistry and genetic testing (\n                    <jats:italic>FH<\/jats:italic>\n                    c.1240A&amp;gt;G, p. Lys414Glu). Despite adjuvant immunotherapy and targeted therapy, rapid bone metastasis occurred postoperatively. This case highlights the aggressive nature of HLRCC-associated RCC, underscores challenges in therapeutic management, and emphasizes the necessity of early genetic testing and multidisciplinary surveillance to improve outcomes.\n                  <\/jats:p>","DOI":"10.3389\/fruro.2026.1907141","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:15:37Z","timestamp":1787199337000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hereditary leiomyomatosis and renal cell carcinoma: a case report and literature review"],"prefix":"10.3389","volume":"6","author":[{"given":"Shuqi","family":"Zuo","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingbo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]},{"name":"Department of Obstetrics and Gynaecology, Shandong Provincial Hospital, Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-014-9735-2","article-title":"Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment","volume":"13","author":"Menko","year":"2014","journal-title":"Familial Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.5334\/jbsr.3687","article-title":"Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome","volume":"108","author":"Mercken","year":"2024","journal-title":"J Belg Soc Radiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.14248","article-title":"Uterine leiomyomas in hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome can be identified through distinct clinical characteristics and typical morphology","volume":"100","author":"Uimari","year":"2021","journal-title":"Acta Obstetricia Et Gynecologica Scandinavica"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0216-RA","article-title":"Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC): a contemporary review and practical discussion of the differential diagnosis for HLRCC-associated renal cell carcinoma","volume":"142","author":"Skala","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02412-w","article-title":"Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism","volume":"129","author":"Valcarcel-Jimenez","year":"2023","journal-title":"Br J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/his.14204","article-title":"Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes","volume":"77","author":"Baniak","year":"2020","journal-title":"Histopathology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154916","article-title":"The use of clinicopathological, immunohistochemistry and molecular detection in the diagnosis of fumarate hydratase-deficient uterine leiomyomas","volume":"253","author":"Zhang","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24449","article-title":"FH deficient uterine leiomyomas-a case series","volume":"10","author":"Kamboj","year":"2024","journal-title":"Heliyon"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.crwh.2023.e00548","article-title":"Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome in a young patient presenting with a large uterus: a case report and review of the literature","volume":"39","author":"Shero","year":"2023","journal-title":"Case Rep Women's Health"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2010.085068","article-title":"Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma","volume":"48","author":"Gardie","year":"2011","journal-title":"J Med Genet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinimag.2020.06.010","article-title":"Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: spectrum of imaging findings","volume":"68","author":"Paschall","year":"2020","journal-title":"Clin Imaging"},{"key":"B12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.semcdb.2019.05.002","article-title":"Fumarate hydratase in cancer: a multifaceted tumour suppressor","volume":"98","author":"Schmidt","year":"2020","journal-title":"Semin Cell Dev Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101963","article-title":"A new missense mutation c.1240A>G in fumarate hydratase gene leads to uterine leiomyoma associated hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome in Chinese","volume":"45","author":"Wang","year":"2024","journal-title":"Transl Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.05.029","article-title":"Genomic profiling and response to immune checkpoint inhibition plus tyrosine kinase inhibition in FH-deficient renal cell carcinoma","volume":"83","author":"Xu","year":"2023","journal-title":"Eur Urol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e165028","DOI":"10.1172\/jci165028","article-title":"Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase-deficient renal cell carcinoma","volume":"133","author":"Zheng","year":"2023","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omae060","article-title":"Sequential therapy for hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinoma: a case report and report of a new family pedigree","volume":"2024","author":"Tsuboi","year":"2024","journal-title":"Oxford Med Case Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3390\/cancers17040573","article-title":"Implications of fumarate hydratase deficiency (FHD) and cancer risk: a window into the clinical and oncological implications of a rare disorder in gynecology","volume":"17","author":"D'Indinosante","year":"2025","journal-title":"Cancers"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200900","article-title":"Bevacizumab and erlotinib in hereditary and sporadic papillary kidney cancer","volume":"392","author":"Srinivasan","year":"2025","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf032","article-title":"The impact of the new WHO classification of renal cell carcinoma on the diagnosis of hereditary leiomyomatosis and renal cell carcinoma","volume":"40","author":"Degenhardt","year":"2025","journal-title":"Nephrology Dialysis Transplant Off Publ Eur Dialysis Transplant Assoc - Eur Renal Assoc"},{"key":"B20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12920-024-01957-w","article-title":"Case report: response to immunotherapy and association with the fh gene in hereditary leiomyomatosis and renal cell cancer-associated renal cell cancer","volume":"17","author":"Gao","year":"2024","journal-title":"BMC Med Genomics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"200\u201313","DOI":"10.1158\/1535-7163.MCT-24-0225","article-title":"Targeting NAD+ metabolism vulnerability in FH-deficient hereditary leiomyomatosis and renal cell carcinoma with the novel NAMPT inhibitor OT-82","volume":"24","author":"Najera","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-22-0874","article-title":"FH variant pathogenicity promotes purine salvage pathway dependence in kidney cancer","volume":"13","author":"Wilde","year":"2023","journal-title":"Cancer Discov"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/apm.13425","article-title":"Fumarate hydratase-deficient renal cell carcinoma: an oncology care institutional experience","volume":"132","author":"Kamboj","year":"2024","journal-title":"APMIS Acta Pathologica Microbiologica Et Immunologica Scandinavica"}],"container-title":["Frontiers in Urology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1907141\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:15:38Z","timestamp":1787199338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1907141\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":23,"alternative-id":["10.3389\/fruro.2026.1907141"],"URL":"https:\/\/doi.org\/10.3389\/fruro.2026.1907141","relation":{},"ISSN":["2673-9828"],"issn-type":[{"value":"2673-9828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1907141"}}